NSCLC, Stage III Clinical Trial
Official title:
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab in Patients With Inoperable Stage III Non-small Cell Lung Cancer: The Indiana Trial
This research aims to incorporate ctDNA analysis into clinical practice to individualize therapy in patients with stage III NSCLC by moving to a treatment-by-marker based approach (as opposed to treatment based on clinical or radiographic evidence of disease).
There is a critical need to identify MRD to determine which patients benefit from checkpoint inhibitor therapy and to optimize and personalize the duration of consolidation Durvalumab. The long-term goal is to incorporate ctDNA analysis into clinical practice to individualize therapy in patients with stage III NSCLC by moving to a treatment-by-marker based approach (as opposed to treatment based on clinical or radiographic evidence of disease). This approach may spare a subset of patients from treatment with unnecessarily excessive cycles of consolidation immunotherapy if they are already cured with CRT alone and individualize the duration of consolidation immunotherapy in patients not cured with CRT. The study team also seek to identify early in the treatment course, patients who are destined not to be cured with consolidation immunotherapy so that alternative strategies can be tested when tumor burden is low. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05386888 -
A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
|
Phase 2 | |
Recruiting |
NCT05128630 -
Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.
|
Phase 2 | |
Active, not recruiting |
NCT05027165 -
Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
|
||
Recruiting |
NCT05311709 -
Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities
|
Phase 2 | |
Recruiting |
NCT04351256 -
Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy
|
Phase 2 | |
Active, not recruiting |
NCT04392505 -
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study
|
Phase 2 | |
Recruiting |
NCT05611879 -
Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
|
Phase 2 | |
Recruiting |
NCT05718297 -
Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06467383 -
A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced
|
||
Recruiting |
NCT04952168 -
Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
|
Phase 2 | |
Recruiting |
NCT04830826 -
A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
|
||
Active, not recruiting |
NCT03999710 -
Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT03454685 -
The Role of Microbiota on the Development of Lung Cancer
|
||
Not yet recruiting |
NCT05177497 -
SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC
|
Phase 2 | |
Recruiting |
NCT04202809 -
Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.
|
Phase 2 | |
Recruiting |
NCT04585490 -
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
|
Phase 3 | |
Recruiting |
NCT04654364 -
Lung Cancer Registry
|
||
Recruiting |
NCT05344209 -
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT03130829 -
To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC
|
N/A | |
Recruiting |
NCT04680377 -
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
|